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Calcium-containing renal stones
LYNWOOD H. SMITH
Division of Nephrology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota
The majority of stones that form within the urinary
tract contain calcium, and various crystalline forms
of calcium oxalate and calcium phosphate are the
types of stones most often found [1,2]. These urinary
tract calculi are not the disease but simply an expres-
sion of varied metabolic disorders that produce
stones of similar crystalline composition; thus, in
evaluating a patient in whom a calcium-containing
stone has developed, it is important for the physician
to consider the possible conditions that may have led
to this complication [31. Outlined in Table 1 is an
etiologic classification of calcium urolithiasis. Before
considering special features of these metabolic disor-
ders, it is helpful to review the general medical evalu-
ation of patients who have calcium-containing renal
stones.
General medical evaluation
The medical evaluation of a patient with calcium
urolithiasis includes consideration of the historical
aspects of the disorder, assessment of the metabolic
activity of the stone formation, and performance of
laboratory studies to define the specific cause of the
stone formation. Although these factors overlap, it is
helpful to consider them first as independent ele-
ments of the medical evaluation and then to discuss
their interrelationships in the diagnosis of the patient
with calcium urolithiasis.
A number of features in the medical history should
be considered (Table 2). The patient's age at the
onset of the problem may help direct the evaluation.
Primary hyperoxaluria, renal tubular acidosis, and
cystinuria commonly occur before puberty. The
peak age at onset for primary hyperparathyroidism is
in the sixth decade and for idiopathic urolithiasis, in
the fourth decade. Idiopathic urolithiasis is much
more common in males than in females, with a ratio
of approximately 5:1. Primary hyperparathyroidism
occurs more commonly in females than in males.
with an approximate ratio of 2:1. A family history of
urolithiasis is often present in patients who have
inherited disorders of metabolism. In the syndrome
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of idiopathic urolithiasis, which includes varied met-
abolic disorders, a family history of stones is also
common, but because of the heterogeneous nature of
the metabolic abnormalities that may be found in
these patients, the patterns of inheritance have not
been established.
Dietary factors in the medical history that may be
helpful include fluid intake and an estimation of the
dietary intake of calcium and oxalate. Medication
such as absorbable alkali, vitamin D, and carbonic
anhydrase inhibitors can promote the complications
of urolithiasis and nephrocalcinosis; therefore, a
careful history of drug ingestion should be taken.
Proprietary drugs containing calcium carbonate and
sodium bicarbonate may often be overlooked. Resi-
dence in geographic areas where urolithiasis is
known to be especially frequent may be an additional
consideration in the medical history of some
patients.
The physical appearance of stones passed or re-
moved surgically may provide clues to their compo-
sition. The patients may know the results of previous
stone analyses or they may have saved a stone. If so,
the stone should be obtained and analyzed. Knowl-
edge of its composition is especially helpful in recog-
nizing patients with cystinuria, uric acid lithiasis, and
the secondary conditions producing struvite (magne-
sium-ammonium-phosphate) stones.
The pattern of the complications with stones
should be documented in each patient. Colic, hema-
tuna, passage of stones and gravel, obstruction, and
surgical manipulations are all important elements in
the medical history. Documented infection and its
associated symptoms should be recorded. If the pa-
tient can recall the types of bacteria present in the
urine, additional insight into the current problem
may be gained (see Dr. Griffith's article, this issue).
The recurring presence of Proteus species in the
bladder urine suggests infected urolithiasis. It is im-
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Table 1. Calcium urolithiasis
I. Renal tubular acidosis
A. Type I distal tubular defect
B. Carbonic anhydrase inhibitors
II. Hypcroxaluric states
A. Primary hyperoxaluria
1. Type I—glycolic aciduria
2. Type II—L-glyceric aciduria
B. Enteric (acquired) hyperoxaluria
III. Hypercalcemic states
A. Primary hyperparathyroidism
B. Immobilization
C. Sarcoidosis
D. Hypervitaminosis D
E. Milk-alkali syndrome
F. Neoplastie disorders
G. Cushing's syndrome
H. Hyperthyroidism
I. Others
IV. Idiopathic renal lithiasis
V. Secondary urolithiasis
A. Infected urolithiasis
B. Obstructive urolithiasis
portant to remember that all too often the presence
of white blood cells (pus) in the urine has led to a
diagnosis of infection and that antimicrobials may
have been given without actual demonstration of
infection by culture. Commonly, patients with stones
in the upper urinary tract will have both pyuria and
hematuria without associated bacteriuria.
There are a number of other medical disorders that
should be sought in the medical history because they
relate to the formation of stones within the urinary
tract. Conditions associated with hypercalcemia and
hypercalciuria may be complicated by calcium uroli-
thiasis (Table 1). The one exception is the hypercal-
cemia of malignancy, in which stone formation is
distinctly rare, perhaps because the hypercalcemia
often heralds the terminal phase of the disease and is
thus of short duration. In patients with gastrointes-
tinal disease, especially after bowel surgery, stone
formation may occur (see Dr. Williams's article, this
issue). Peptic ulcer disease or pancreatitis may have
been the presenting sign of primary hyperparathy-
roidism. Symptoms of dyspepsia, heartburn, or ul-
Table 2. Features of the medical history in the evaluation of
calcium urolithiasis
I. Age at onset
II. Sex
Ill. Family history
IV. Diet and drug history
V. Geographic residence
VI. Clinical considerations
A. Nature of stones
B. Stone history
C. History of urinary tract infection
D. Other medical disorders and surgery
F. Previous roentgenograms
cers may have been treated with absorbable alkali
and milk, and patients with glaucoma may have been
treated with carbonic anhydrase inhibitors; both of
these situations would increase the tendency to the
formation of stones.
Previous roentgenograms may be available with
which to assess the nature of the stone formation and
to help in determining its progression. As will be
discussed subsequently, such X-ray films are vital in
determining the metabolic activity of the stones.
A major problem in evaluating a patient with cal-
cium urolithiasis relates to the metabolic activity of
the stone formation. Irrespective of the underlying
cause, stone formation varies among patients with
the same disorder. Some patients are constantly
forming stones and other patients do not form stones
at all, and between these extremes is a full spectrum
of variations. An excellent example of this is primary
hyperparathyroidism, in which no more than 50% of
the patients with surgically proven hyperparathy-
roidism have ever had a stone 11411. For this reason, it
is extremely important to establish criteria for meta-
bolic activity if one is to use long-term therapy ap-
propriately for those patients who are actively form-
ing stones and who therefore need it.
We established arbitrary criteria of the activity of
stone formation in 1965 when our Stone and Parathy-
roid Clinics were established [5]. "Surgical activity"
is said to be present when the patient has colic,
obstruction, or infection associated with a stone
which often requires surgical intervention. This in
itself does not imply metabolic activity, because the
stone causing the trouble may have been formed long
before, without there having been any subsequent
change in size.
"Metabolically active urolithiasis" is considered
to be present when one or more of the following
criteria are satisfied: 1) roentgenographic evidence of
new stone formation within the past year, 2) roent-
genographic evidence of stone growth within the past
year, or 3) the passage of documented gravel within
the past year. If none of these criteria is present and
previous roentgenograms are adequate, then the
stone formation is considered "inactive" and the
patient is managed by a high fluid intake and periodic
follow-up. If infected or obstructive urolithiasis is
present, the metabolic activity cannot be evaluated
until this secondary problem has been eliminated.
When previous roentgenograms are not available
or are inadequate for evaluation of the activity of the
stone formation, a category of "indeterminate meta-
bolic activity" is assigned. These patients are care-
fully instructed with regard to a high fluid intake and
dietary restriction when indicated, and they are fol-
lowed periodically with roentgenograms (plain film
Calcium urolithiasis 385
with tomographic views) until a classification of the
metabolic activity can be made. In the follow-up
(mean of eight years) of 101 consecutive patients
with idiopathic urolithiasis in whom the metabolic
activity of the stone formation was initially termed
"indeterminate," 64 patients (63%) were found to
have "metabolically inactive urolithiasis" on the
conservative treatment program [3]. Had these pa-
tients been started on specific therapy without estab-
lishment of the need for it, approximately two-thirds
of the patients would have been committed to unnec-
essary life-long therapy.
There are obvious limitations to this classification
of metabolic activity. First, the evaluation is limited
to the resolution obtained on roentgenograms. Al-
though this resolution has been improved by the use
of tomography, there remains a minimum stone size
(no less than approximately 1 mm) that can be identi-
fied, and this is influenced by the density of the
stone. Second, if the stone moves and reorients its
axis, its size may falsely appear to have changed
because of its irregular shape. Third, and perhaps
most important, the complication of new stone for-
mation or growth must occur before therapy has
been instituted. In spite of these limitations, the
clinical criteria of metabolic activity have been very
useful in helping us to restrict specific therapy to
those patients who need it.
The laboratory evaluation of the patient with cal-
cium urolithiasis should be influenced by the medical
history and the preliminary assessment of metabolic
activity. Since continued follow-up of the patient
with urolithiasis is the cornerstone to successful
management, the laboratory evaluation of the patient
often can proceed stepwise. Outlined in Table 3 is
the general laboratory evaluation we use in patients
with calcium urolithiasis. To this, special tests are
added to define specific metabolic disorders when
indicated. The list of tests is long and many of them
are costly, and for this reason we believe that it is
extremely important to approach each patient indi-
vidually and not to establish a "routine" for all
patients seen for evaluation of calcium urolithiasis.
For instance, the laboratory evaluation of an asymp-
tomatic 60-yr-old man whose three stones have not
changed on roentgenograms over the past five years
might include serum calcium, phosphorus, uric acid,
and creatinine determinations, urinalysis, and urine
culture. If these studies are normal or negative, then
regular follow-up of his urolithiasis can be done at
the time of his annual medical examination. Addi-
tional studies would be indicated only if there was a
change in the status of the activity of his stone
formation.
These general considerations in the medical evalu-
Table 3. Laboratory evaluation of calcium urolithiasis
I. Serum
Calcium x 3
Phosphorus
Uric acid
Creatinine/blood urea nitrogen
Alkaline phosphatase
Protein electrophoresis
Immunoreactive parathyroid hormone
II. Urine
Urinalysis
Urine culture and sensitivity
Urinary pH (fasting state)
III. Urine chemistry (24-hr collection)
Calcium
Phosphorus
Uric acid
Oxalate
Cystine
Creatinine
IV. Renal function
Creatinine clearance (inulin and PAH clearance)
V. Roentgenograms
VI. Stone analysis (if available)
ation of the patient with calcium urolithiasis can be
applied now to the metabolic disorders listed in Ta-
ble 1 and can be made more specific for each of these
disorders. Hyperoxaluria (see Dr. Williams's article,
this issue) and secondary urolithiasis (see Dr. Grif-
fith's article, this issue) have been discussed else-
where in this symposium and will not be considered
further.
Renal tubular acidosis
Renal tubular acidosis (RTA) is associated with
disturbances in acid-base balance by the kidney
[6,71. Type I RTA is characterized by an inability of
the distal nephron to generate or maintain steep
luminal-peritubular hydrogen ion gradients. In this
condition, conservation of bicarbonate and produc-
tion of ammonia are usually normal. The patient is
unable to excrete urine of a pH less than 5.8, even in
the presence of systemic acidosis. Hyperchloremic
acidosis, hypokalemia, and urinary wasting of so-
dium, potassium, calcium, and phosphorus occur.
Calcium urolithiasis, nephrocalcinosis, muscle
weakness, and osteomalacia may develop.
Type II RTA is associated with a proximal renal
tubular defect in reabsorption of bicarbonate without
the distal tubular abnormalities. To date, urolithiasis
and nephrocalcinosis have not occurred with Type II
RTA.
Both defects have been reported in a few patients.
RTA may be transmitted as an autosomal-dominant
pattern of inheritance. More commonly, it occurs
spontaneously or in association with systemic
diseases.
The diagnosis of type I RTA is made by demon-
strating an inability to acidify urine below a pH of 5.8
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in the presence of systemic acidosis and in the ab-
sence of abnormalities in metabolism of bicarbonate
and ammonia by the kidney. Measurement of the pH
(with a pH meter) of the second voided morning
urine after the patient has fasted overnight provides a
simple method for screening patients with calcium
urolithiasis. If the urinary pH is not less than 5.5, a
solution of ammonium chloride (500 mg/S ml) is given
orally at a dosage of 100 mg/kg per 24 hr. Bicarbon-
ate and pH are measured in the plasma and urine. If
the urinary pH remains above 5.8 when the plasma
bicarbonate concentration decreases below 20 mEq/
liter in the absence of a renal leak of bicarbonate, the
diagnosis of type I RTA is confirmed, and the admin-
istration of ammonium chloride is stopped. Because
bacterial metabolism may alter urinary pH, measure-
ment of urinary pH must be done only after it has
been shown by culture that the patient is free of
bacteriuria.
Treatment of patients with type I RTA involves
correction of their metabolic abnormalities. Replace-
ment of sodium, potassium, and base is usually re-
quired. It is important to remember that with signifi-
cant systemic acidosis, serum potassium may be
normal in spite of a major deficit in total body potas-
sium. Replacement of base alone in this setting may
be lethal. Base requirements usually range from 60 to
120 mEq per day and should be given in divided
doses either as sodium bicarbonate or as citrate solu-
tion. Serum potassium should be monitored care-
fully, and replacement should be provided as
needed. The stone formation and nephrocalcinosis in
some of these patients will be arrested with this
replacement program. When stone formation and
nephrocalcinosis have progressed in spite of ade-
quate metabolic replacement therapy, oral ortho-
phosphate has been used effectively [81.
Carbonic anhydrase inhibitors, which are used pri-
marily in patients with glaucoma, can produce abnor-
malities in acid-base metabolism in the kidney [9]. In
a small number of these patients, calcium urolithiasis
will develop. In our experience, patients in whom
this complication develops have often, but not al-
ways, a past history of stone formation that was
inactive until the medication was started. Stopping
use of the carbonic anhydrase inhibitor, if possible,
will usually arrest the stone formation; if this is not
possible, oral orthophosphate has been used effec-
tively to prevent further stone formation [81.
Hypercalcemic states
Included in Table 1 are some of the disorders that
can cause hypercalcemia and be associated with
urolithiasis. The initial step in recognizing this com-
plication of those metabolic disorders is the identifi-
cation of increased serum concentration of calcium.
Stated normal ranges in healthy subjects have varied
widely, even when the same method of chemical
analysis has been employed. A range of serum cal-
cium of 9 to 11 mgldl, which has been commonly
used in the past as the normal range, would not have
led to the diagnosis of hypercalcemia in 31% of the
patients in one series who had surgically documented
primary hyperparathyroidism with complications of
their disease [41. In our laboratory, the normal range
of serum calcium is 8.9 to 10.1 mg/dl, which was
established by the careful studies by Keating et al
[10]. The normal range may vary, depending on the
method of chemical analysis, but it should be estab-
lished within each clinical laboratory. Serum protein
content will affect the protein-bound fraction of cal-
cium within the serum; therefore, it is also important
to measure serum concentration of proteins when
evaluating that of serum. Ideally, three or more serial
serum calcium determinations are used to establish
the presence of hypercalcemia.
Hypercalciuria (greater than 300 mg of calcium in
the urine per 24 hr when on a normal calcium intake)
usually accompanies hypercalcemia and has been
thought to be important in the formation of stones
within the urinary tract. This hypercalciuria may be
masked if there is significant impairment of renal
function (a GFR of less than 30 mI/mm). Hypercalci-
uria may not be present in some patients with pri-
mary hyperparathyroidism when the effect of para-
thyroid hormone in increasing the tubular
reabsorption of calcium is greater than the effect of
hypercalcemia in increasing the filtered load of cal-
cium in the glomerulus. The most common crystal
system occurring in stones with hypercalcemic disor-
ders is calcium phosphate, but calcium oxalate may
also be present.
Special laboratory studies that have been particu-
larly helpful in the differential diagnosis of hypercal-
cemic states include roentgenograms of bone and
measurement of serum immunoreactive parathyroid
hormone. Subperiosteal bone resorption, which is
most commonly demonstrated on roentgenograms of
the hands with the use of high-quality industrial film,
is diagnostic of hyperparathyroidism [111. The pres-
ence of Paget's disease and neoplastic involvement
of the bone are other examples in which roentgeno-
grams of bone may be helpful in the differential
diagnosis of hypercalcemia. The concentration of
serum immunoreactive parathyroid hormone is ele-
vated in hyperparathyroid states, whereas it is com-
monly low or undetectable in the other metabolic
abnormalities associated with hypercalcemia [12,
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13]. Stress tests including phosphate deprivation,
parathormone infusion, calcium infusion, cortisone
suppression, and thiazide administration have been
reported to be useful in the differential diagnosis of
hypercalcemia [14—19].
Neoplastic disorders are the most common cause
of hypercalcemia, yet stone formation is rare. As
previously stated, this may be related to the ten-
dency for the hypercalcemia with malignancy to be a
late or terminal complication. Primary hyperparathy-
roidism is the most common hypercalcemic state
associated with calcium urolithiasis. Approximately
50% of patients with surgically proven hyperparathy-
roidism have evidence of stone formation, and ap-
proximately 5% of the adult stone formers will have
this endocrinopathy. Immobilization, particularly in
adolescent patients with active bone formation, may
be complicated by hypercalcemia and hypercalci-
uria, with subsequent formation of stones within the
urinary tract. The milk-alkali syndrome and hyper-
vitaminosis D, now rare disorders, can be associated
with calcium urolithiasis, nephrocalcinosis, and renal
insufficiency. Sarcoidosis with its associated hyper-
sensitivity to vitamin D may produce massive hyper-
calciuria (greater than 700 mg/24 hr) and hypercal-
cemia. With all of these disorders, treatment is based
on accurate diagnosis of the underlying metabolic
disorder and subsequent correction of the hypercal-
cemia and associated hypercalciuria when possible.
With such correction, stone formation within the
urinary tract ceases, unless some other cause is pres-
ent, such as infected urolithiasis, cystinuria, or idio-
pathic hypercalciuria.
Idiopathic urolithiasis
The syndrome of idiopathic urolithiasis includes
various metabolic disorders and is the most common
cause of calcium urolithiasis in industrialized coun-
tries. This diagnosis is currently applied to perhaps
80% of patients who have formed stones within the
urinary tract. It remains a diagnosis of exclusion,
made only when all other potential causes of stone
formation have been ruled out. Although definable
metabolic abnormalities have been described in pa-
tients with this syndrome, the underlying mecha-
nisms of these various abnormalities are poorly
understood.
Typically, these patients have normal serum con-
centrations of calcium, low normal or low serum
concentrations of phosphorus, and hypercalciuria
when on an average calcium intake (in 50 to 75% of
patients). Calcium oxalate is the most common crys-
tal found in the stones of these patients, but calcium
phosphate (as pure or mixed stones) and uric acid
(usually as mixed stones) can be present. This syn-
drome is more common in males than in females, and
the initial presentation of symptoms is usually in the
third or fourth decade of life. A family history of
stone formation is often present in these patients.
Little is known of the patterns of inheritance, primar-
ily because of our lack of knowledge concerning the
underlying metabolic abnormalities.
The recognized disturbances of metabolism in pa-
tients with idiopathic urolithiasis can be divided into
two groups, based on the urinary excretion of cal-
cium. In the first group (50 to 75%), the patients have
hypercalciuria on an average calcium intake. These
patients can be divided further into those with in-
creased absorption of calcium from the intestine (ab-
sorptive hypercalciuria) and those with persistent
renal leak of calcium into the urine (renal hypercalci-
uria). Absorptive hypercalciuria and renal hypercal-
ciuria probably constitute the two major variants of
idiopathic hypercalciuria.
An abnormality of calcium absorption from the
intestine was first noted by Peacock, Knowles, and
Nordin [20]. They showed, in patients with idio-
pathic urolithiasis and hypercalciuria who had fasted
overnight, that the urinary concentration of calcium
decreased to within the normal range. More recently,
Pak et al [211 have confirmed these observations and
devised a simple test for the differential diagnosis of
hypercalciuria. They measured, in a group of pa-
tients with hypercalciuria, the urinary excretion of
calcium, cyclic AMP, and creatinine in a two-hour
sample of urine after an overnight fast and in a four-
hour sample of urine after administration of 1 g of
calcium by mouth. In patients with an absorptive
defect in the intestine, the fasting urinary calcium
was less than 0.11 mg/mg of urinary creatinine, and it
increased to elevated levels after a calcium load
(more than 0.2 mg/mg of creatinine). Recent studies
of vitamin D metabolism in patients with absorptive
hypercalciuria have demonstrated an increase in
plasma 1 ,25-dihydroxy vitamin D, an abnormality
that may be related in part to the low serum levels of
phosphorus in these patients [221.
Another abnormality associated with hypercalci-
uria in patients with idiopathic urolithiasis—renal
hypercalciuria—was suggested by Coe et al [231.
They found an increased concentration of immuno-
reactive parathyroid hormone in 26 of 40 patients
with idiopathic hypercalciuria, and this returned to
normal or nearly normal levels when the hypercalci-
uria was corrected with the administration of thia-
zide diuretics. These observations led the authors to
suggest that there was a primary renal leak of cal-
cium, with an associated secondary hyperparathy-
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roidism. Pak et a! [21] found this abnormality in only
10% of the patients they studied with the method of
fasting and calcium-loading described above. Pea-
cock et al [20] found no examples of renal hypercal-
ciuria in the patients they studied. The primary
mechanism of the renal leak is unknown.
Within the group of patients with idiopathic uroli-
thiasis and hypercalciuria, there may be patients
with high normal or slightly elevated serum concen-
trations of calcium and resorptive hypercalciuria
who later prove to have primary hyperparathyroid-
ism. Yendt and Gagne [24], utilizing ionized calcium,
were able to show elevated levels of calcium in a
group of women who subsequently were shown by
surgery to have primary hyperparathyroidism.
The second major group of patients with idiopathic
urolithiasis do not have hypercalciuria on an average
calcium intake. Abnormalities described in these pa-
tients include primary defects of crystal growth and
aggregation inhibitors, increased urinary excretion of
oxalate (see Dr. Williams's article, this issue), in-
creased alkalinity of the urine, and abnormalities in
uric acid metabolism (see Dr. Coe's article, this is-
sue). Although these metabolic abnormalities have
been recognized in patients with idiopathic uroli-
thiasis, the underlying causes remain unknown.
Inhibitors of crystal growth and aggregation found
in the urine are discussed in detail elsewhere in this
symposium (see Dr. Fleisch's article, this issue).
Thomas [25] has reported a gross decrease in the
low-molecular-weight nonhydrolyzable inhibitors of
calcium phosphate crystal growth in patients with
active stone formation due to idiopathic urolithiasis.
Robertson and Peacock [26] have noted a decrease
in the large-molecular-weight inhibitors of calcium
oxalate crystal aggregation in stone-formers with re-
current calcium oxalate stones due to idiopathic urol-
ithiasis. Again, the mechanisms of these deficiencies
are unknown.
Robertson, Peacock, and Nordin [27] reported
two groups of patients with idiopathic urolithiasis
without hypercalciuria. The first group were forming
calcium oxalate stones and had mild increases in the
urinary excretion of oxalate without increases in
excretion of glycolate or L-glyceric acid. The second
group were forming calcium phosphate stones and
had persistently alkaline urine while eating their nor-
mal diet, yet they had no renal abnormality in terms
of acid-handling. Their response to an ammonium
chloride load was normal. Again, the underlying
mechanisms of these abnormalities are unknown.
Coe and Kavalach [28] have suggested an addi-
tional abnormality in patients with idiopathic uro-
lithiasis, namely normocalciuria and recurrent cal-
cium oxalate stones. They have found a persistent
elevation of the urinary excretion of uric acid in
some of these patients without hyperuricemia. Based
on the observations of Lonsdale [29] on the close
dimensional similarity of many of the crystal phases
of the common crystalline components of urinary
calculi, they suggested that the uric acid or sodium
acid urate crystals could form spontaneously in this
setting and induce nucleation of calcium oxalate by
the mechanism of epitaxy. Once the calcium oxalate
crystals had formed, they could aggregate and grow
in patients with idiopathic urolithiasis when the state
of saturation was metastable for calcium oxalate.
This mechanism is reviewed in more detail elsewhere
in the symposium (see Dr. Coe's article, this issue).
A recent study by Robertson et al [30] reported that
the urinary saturation of uric acid, sodium urate, and
ammonium urate was below the formation product in
all but two of their patients with idiopathic uro-
lithiasis and calcium oxalate stone formation. For
spontaneous uric acid crystal formation to occur, it is
a prerequisite for the epitaxy theory that uric acid
saturation be above the formation product at which
spontaneous nucleation of crystals would occur.
Current therapy of idiopathic urolithiasis, which is
discussed in detail elsewhere in the symposium, is
directed toward correcting the abnormalities de-
scribed above. Perhaps in none of the many meta-
bolic disorders associated with urolithiasis is the con-
cept of metabolic activity more important than in
idiopathic urolithiasis. Stone formation is often vari-
able between patients and within the same patient.
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